NCR Online Journal

Chronic Hepatitis B Virus Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products | Major Companies- Vedanta Biosciences, Janssen Pharma, and Others

 Breaking News
  • No posts were found

Chronic Hepatitis B Virus Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products | Major Companies- Vedanta Biosciences, Janssen Pharma, and Others

April 24
11:01 2023
Chronic Hepatitis B Virus Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products | Major Companies- Vedanta Biosciences, Janssen Pharma, and Others

DelveInsight’s, “Chronic Hepatitis B Virus Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Chronic Hepatitis B Virus pipeline landscape. It covers the chronic hepatitis B Virus pipeline drug profiles, including Chronic Hepatitis B Virus clinical trials and nonclinical stage products. It also covers the Chronic Hepatitis B Virus pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Chronic Hepatitis B Virus Pipeline Report

 

  • DelveInsight’s Chronic Hepatitis B Virus Pipeline analysis depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Chronic Hepatitis B Virus treatment.

 

  • The leading Chronic Hepatitis B Virus Companies include Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, and others

 

  • Promising Chronic Hepatitis B Virus Pipeline Therapies includes Pradefovir, DA 2802, VIR-2218, AB-729, Selgantolimod, ATI-2173, ASC42, Hepalatide, QL-007, Antroquinonol, HEC121120, APG-1387,  GSK3228836, JNJ-73763989, JNJ-56136379, Vonafexor,  T101, BRII-179, aVTP-300, PA1010, P1101, NCO-48, HRS5091, EDP-514, CKD-388, LP-128, VNRX 9945, ZM-H1505R, ISA104, RG6346, HepTcell, RO7049389, RO7020531, GST-HG141, PBGENE-HBV, SBT8230, and others.

 

  • The Chronic Hepatitis B Virus Companies and academics are working to assess challenges and seek opportunities that could influence in Chronic Hepatitis B Virus Infection R&D. The Chronic Hepatitis B Virus pipeline therapies under development are focused on novel approaches to treat/improve in Chronic Hepatitis B Virus Infection. 

 

To explore more information on the latest breakthroughs in the Chronic Hepatitis B Virus Pipeline treatment landscape of the report, click here @ Chronic Hepatitis B Virus Pipeline Outlook

 

Chronic Hepatitis B Virus Overview

Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is often transmitted via body fluids like blood, semen, and vaginal secretions. The majority (more than 95%) of immunocompetent adults infected with HBV can clear the infection spontaneously.

 

Recent Developmental Activities in the Chronic Hepatitis B Virus Treatment Landscape

 

  • In January 2022, VBI Vaccines announced that the first patient had been dosed in a second Phase 2a/2b clinical study evaluating VBI-2601 (BRII-179), an immunotherapeutic candidate targeting chronic hepatitis B virus (HBV).

 

  • In March 2022, Brii Biosciences Limited presented new data from a Phase II randomized, double-blind, placebo-controlled trial of BRII-835 (VIR-2218) in Chinese patients with chronic hepatitis B virus (HBV) infection, at the 31st Conference of Asian Pacific Association for the Study of the Liver (APASL) 2022. The data demonstrated that BRII-835 (VIR-2218), an investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi), resulted in a dose-dependent reduction in hepatitis B surface antigen (HBsAg) in Chinese patients with chronic HBV infection who received two doses of BRII-835 (VIR-2218). Similar HBsAg reductions were observed in both HBeAg- and HBeAg+ patients. In addition, BRII-835 (VIR-2218) was well-tolerated, with all treatment-emergent adverse events (TEAEs) reported as mild or moderate, and no clinically significant alanine transaminase (ALT) elevations were observed.

 

  • In March 2022, Aligos Therapeutics halted the development of ALG-020572, which was being developed in patients with chronic hepatitis B (CHB). The first CHB cohort of Study ALG-020572-401 was stopped after one of the patients had a serious adverse event (SAE) causing a brief hospitalization.The patient showed a significant increase in alanine aminotransferase (ALT) after multiple dosing of 210 mg of the therapy. Aligos noted that this was just one of four chronic hepatitis B (CHB) subjects in the cohort to have the potentially drug-related ALT flares, indicative of liver toxicity.

 

  • In December 2021, Arbutus Biopharma Corporation and Qilu Pharmaceutical announced that the companies had entered into an exclusive licensing agreement and strategic partnership for the development and commercialization of AB-729 for the treatment or prevention of hepatitis B in mainland China, Hong Kong, Macau and Taiwan.Under terms of the agreement, Qilu payed Arbutus $40 million up front, as well as up to $245 million in development, regulatory and sales milestones. In addition, Qilu made a $15 million equity investment in Arbutus at a price of $4.19 per share.

 

  • In October 2021, Antios Therapeutics and Assembly Biosciences announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection.

 

For further information, refer to the detailed Chronic Hepatitis B Virus Unmet Needs, Chronic Hepatitis B Virus Market Drivers, and Chronic Hepatitis B Virus Market Barriers, click here for Chronic Hepatitis B Virus Ongoing Clinical Trial Analysis

 

Chronic Hepatitis B Virus Emerging Drugs Profile

 

  • Pradefovir: Ligand Pharmaceuticals

Pradefovir is an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of hepatitis B virus (HBV) infection. The drug is developing using Ligand’s HepDirect technology. Currently the product is in Phase III stage of development for the treatment of Chronic Hepatitis B.

 

  • RG6346: Dicerna Pharmaceuticals

RG6346 is an investigational GalXC™ RNAi therapeutic candidate in development in collaboration with Roche for the treatment of chronic HBV infection. RG6346 is designed to employ RNA interference to selectively knock down specific genes involved in the creation of HBV messenger RNA (mRNA) and the entry of the virus into liver cells. Preclinical data have demonstrated greater than 99.9% reduction in circulating HBsAg, as observed in mouse models of HBV infection. Unlike current therapies that typically provide long-term suppression of the virus, RG6346 has the potential to provide a functional cure for patients living with chronic HBV. Dicerna is currently conducting a Phase II trial of RG6346 in adult patients with chronic HBV infection.

 

Chronic Hepatitis B Virus Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Chronic Hepatitis B Virus Infection. The companies which have their Chronic Hepatitis B Virus Infection drug candidates in the most advanced stage, i.e. Phase III include, Ligand Pharmaceuticals.

 

Request a sample and discover the recent advances in Chronic Hepatitis B Virus Ongoing Clinical Trial Analysis and Medications, click here @ Chronic Hepatitis B Virus Treatment Landscape

 

Scope of the Chronic Hepatitis B Virus Pipeline Report

 

  • Coverage- Global

 

  • Chronic Hepatitis B Virus Companies- Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, and others

 

  • Chronic Hepatitis B Virus Pipeline Therapies- Pradefovir, DA 2802, VIR-2218, AB-729, Selgantolimod, ATI-2173, ASC42, Hepalatide, QL-007, Antroquinonol, HEC121120, APG-1387,  GSK3228836, JNJ-73763989, JNJ-56136379, Vonafexor,  T101, BRII-179, aVTP-300, PA1010, P1101, NCO-48, HRS5091, EDP-514, CKD-388, LP-128, VNRX 9945, ZM-H1505R, ISA104, RG6346, HepTcell, RO7049389, RO7020531, GST-HG141, PBGENE-HBV, SBT8230, and others.

 

  • Chronic Hepatitis B Virus Pipeline Segmentation: Product Type, Molecule Type, Route of Administration 

 

Dive deep into rich insights for drugs for Chronic Hepatitis B Virus Market Drivers and Chronic Hepatitis B Virus Market Barriers, click here @ Chronic Hepatitis B Virus Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic Hepatitis B Virus Infection: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Hepatitis B Virus Infection  – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pradefovir: Ligand Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. RG6346: Dicerna Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. VIR-3434: Vir Biotechnology
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. SBT8230: Silverback Therapeutics
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Chronic Hepatitis B Virus Infection  Key Companies
  24. Chronic Hepatitis B Virus Infection  Key Products
  25. Chronic Hepatitis B Virus Infection – Unmet Needs
  26. Chronic Hepatitis B Virus Infection – Market Drivers and Barriers
  27. Chronic Hepatitis B Virus Infection – Future Perspectives and Conclusion
  28. Chronic Hepatitis B Virus Infection  Analyst Views
  29. Chronic Hepatitis B Virus Infection  Key Companies
  30. Appendix

 

Got Queries? Find out the related information on Chronic Hepatitis B Virus Mergers and acquisitions, Chronic Hepatitis B Virus Licensing Activities @ Chronic Hepatitis B Virus Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles